Companies › Actuate Therapeutics
1 active drug program in 4 registered trials: 3 Phase 2, 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Elraglusib (ING-41) Glycogen synthase kinase-3 beta inhibitor | GSK3B | Phase 2 | Cancer; Pancreatic Adenocarcinoma; Salivary Gland Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03678883 | Elraglusib (ING-41) | Phase 2 | Cancer | Oncology | Jun 2026 |
| NCT05077800 | Elraglusib (ING-41) | Phase 2 | Pancreatic Adenocarcinoma | Oncology | Dec 2026 |
| NCT05010629 | Elraglusib (ING-41) | Phase 2 | Salivary Gland Cancer | Oncology | Apr 2027 |
| NCT06896188 | Elraglusib (ING-41) | Phase 1 | Pancreatic Adenocarcinoma | Oncology | Mar 2028 |
Cash of $4m on 2026-06-30; operating cash outflow about $19m a year; runway about 3 months at that burn, to Sep 2026; 0 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Oncolytics Biotech Cardiff Oncology TuHURA Biosciences Inhibrx Biosciences Vasgene Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.